Modality
Radioligand
MOA
IL-23i
Target
AuroraA
Pathway
Autophagy
UCTTR Amyloidosis
Development Pipeline
Preclinical
Nov 2019
→ May 2028
PreclinicalCurrent
NCT06551124
766 pts·UC
2019-11→2028-05·Active
766 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-05-032.1y awayInterim· UC
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
Preclinical
Active
Catalysts
Interim
2028-05-03 · 2.1y away
UC
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06551124 | Preclinical | UC | Active | 766 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| GSK-6983 | GSK | Phase 2 | ALK | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| Zenotapinarof | Vertex Pharma | Preclinical | CD38 | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| ARG-6988 | Argenx | Preclinical | AuroraA | |
| Bemasotorasib | Exelixis | Phase 2 | CD38 | |
| Tirasotorasib | Viking Therapeutics | Phase 1 | CFTR | |
| Semamavacamten | Ideaya Bio | Phase 1/2 | AuroraA | |
| Cevinaritide | Praxis Precision | Phase 3 | AuroraA |